Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.9741
- Book/Share 2.5079
- PB 19.9852
- Debt/Equity 1.856
- CurrentRatio 4.9795
- ROIC 0.1086
- MktCap 10908217040.0
- FreeCF/Share 0.5326
- PFCF 91.2776
- PE 58.0858
- Debt/Assets 0.5562
- DivYield 0
- ROE 0.3817
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX® , an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone levels due to certain medical conditions, available to patients through the Hims & Hers platform in the coming months. This marks the first time Hims & Hers will offer an FDA-approved oral testosterone therapy, underscoring KYZATREX's position as a leader in the testosterone therapy space.
Read More
Hims & Hers: The Next Chapter For Investors
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Positive
Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a brand moat and delivers 76% gross margins.
Read More
Hims & Hers launches treatment plans for low testosterone
Published: September 10, 2025 by: Reuters
Sentiment: Positive
Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone.
Read More
Hims & Hers Expanding Partnerships to Build a Global Health Ecosystem
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its digital health footprint with global moves, top-tier partnerships and more than 1,500 providers.
Read More
HIMS' Personalized Wellness Platform Expands Preventive Care Access
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.
Read More
HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers expands globally, while Amwell leans on federal contracts and software growth. Let's see which has the edge in earnings growth & strategic expansion.
Read More
Hims & Hers Scales Growth Through Subscriptions and Care Expansion
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS fuels growth through subscriptions, expanding care offerings and building proprietary health infrastructure at scale.
Read More
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Published: August 25, 2025 by: Benzinga
Sentiment: Positive
Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc RKT, Oscar Health Inc OSCR, and Hims & Hers Health Inc HIMS are sitting at the top of the market's short-interest leaderboard, each with more than a quarter of their float sold short.
Read More
HIMS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the August 25th Deadline for the Hims Lawsuit and Urges Investors to Contact The Firm
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
Read More
DEADLINE ALERT for HIMS, IRBT, and CNC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Hims & Hers: Personalized Care To Sustain Revenue Growth Despite GLP-1 Hiccup
Published: August 22, 2025 by: Seeking Alpha
Sentiment: Positive
I remain bullish on Hims & Hers Health due to its resilient subscriber growth and strong positioning in the expanding personalized care and telehealth markets. Despite the loss of the GLP-1 contract with Novo Nordisk, HIMS is adapting quickly, maintaining revenue growth and benefiting from high customer retention and positive feedback. The company's financials show sustained profitability, robust revenue growth, and a premium valuation justified by its superior performance compared to competitors like Teladoc.
Read More
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - Hagens Berman
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit. The lawsuit alleges that Hims made misleading statements about its GLP-1 weight-loss drug business and its partnership with Novo Nordisk, which was abruptly canceled.
Read More
MONDAY DEADLINE: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Class Action by August 25, 2025
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Berger Montague , a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims" …
Read More
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HIMS DEADLINE REMINDER: Important August 25, 2025 Deadline Reminder in Hims & Hers Health, Inc. Securities Class Action Lawsuit
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
RADNOR, Pa. , Aug. 22, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period").
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Hims & Hers Health, Inc.(HIMS) Shareholders
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025.
Read More
HIMS FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action – HIMS
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 21, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). IF YOU SUFFERED A LOSS ON YOUR HIMS INVESTMENTS, CLICK HERE BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
The Gross Law Firm Reminds Hims & Hers Health, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – HIMS
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).
Read More
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets
Published: August 21, 2025 by: MarketBeat
Sentiment: Positive
Most investors have noticed that most stocks in the healthcare sector have declined to levels not seen in a while, making this an area of interest for those looking into the next potential upswing in their portfolios. However, for those who are okay with individual stock picking and taking on a bit more risk, there is one narrative to follow in the coming months.
Read More
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - Hagens Berman
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit. The lawsuit alleges that Hims made misleading statements about its GLP-1 weight-loss drug business and its partnership with Novo Nordisk, which was abruptly canceled.
Read More
Hims & Hers Health Inc. (NYSE: HIMS) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
Published: August 20, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 20, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). The firm is examining whether Hims & Hers, during the Class Period from April 29, 2025 through June 22, 2025 (the "Class Period"), violated federal securities laws by making false or misleading statements to investors.
Read More
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of Hims & Hers' executives with violations of the Securities Exchange …
Read More
HIMS Investors Have the Opportunity to Lead the Hims & Hers Health Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options
Read More
HIMS Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health, Inc. (HIMS) Investors of Filing Deadline in Class Action Lawsuit
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
RADNOR, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Read More
Hims & Hers Fuels Growth via Market Expansion and New Care Verticals
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS eyes long-term growth with new hormonal health offerings, international expansion and high GLP-1 retention.
Read More
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Published: August 18, 2025 by: Fast Company
Sentiment: Positive
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637